Clinical Oncology
Volume 22, Issue 1 , Pages 27-35 , February 2010

Induction Chemotherapy Followed by Chemoradiation in Locally Advanced Pancreatic Cancer: an Effective and Well-tolerated Treatment

  • E. Hudson

      Affiliations

    • Clinical Oncology, Velindre Hospital, Cardiff, UK
    • ,
  • C. Hurt

      Affiliations

    • Cardiff University, Cardiff, UK
    • ,
  • D. Mort

      Affiliations

    • Clinical Oncology, Velindre Hospital, Cardiff, UK
    • ,
  • A.E. Brewster

      Affiliations

    • Clinical Oncology, Velindre Hospital, Cardiff, UK
    • ,
  • N. Iqbal

      Affiliations

    • Clinical Oncology, Velindre Hospital, Cardiff, UK
    • ,
  • G. Joseph

      Affiliations

    • Clinical Oncology, Velindre Hospital, Cardiff, UK
    • ,
  • T.D.L. Crosby

      Affiliations

    • Clinical Oncology, Velindre Hospital, Cardiff, UK
    • ,
  • S. Mukherjee

      Affiliations

    • Clinical Oncology, Velindre Hospital, Cardiff, UK
    • Corresponding Author InformationAuthor for correspondence: S. Mukherjee, Centre for Oncology, Northampton General Hospital, Cliftonville, Northampton NN1 5BD,UK. Tel/Fax: +441604523470.

Received 10 April 2009 ,Revised 7 September 2009 ,Accepted 10 September 2009.

References 

  1. Cancer Research UK . Cancer statistics. Available from: http://info.cancerresearchuk.org/cancerstats/
  2. Mukherjee S, Hudson E, Reza S, et al. Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer (LANPC). Clin Oncol (R Coll Radiol). 2008;20(7):535–540
  3. Jackson A, The pancreatic subgroup of ACCORN . Survey of current UK practice of pancreatic cancer management by clinical oncologists. In: Proceedings of combined chemo-radiotherapy for GI cancer. London: BIR; 2007;
  4. Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27:2269–2277
  5. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592–1599
  6. Sultana A, Tudur SC, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007;96:1183–1190
  7. Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210
  8. Available from: http://www.ncrn.org.uk/
  9. Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol. 2008;26(Suppl.):abstract 4506
  10. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–331
  11. Brade A, Brierley J, Oza A, et al. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I–II study. Int J Radiat Oncol Biol Phys. 2007;67(4):1027–1036
  12. Ko AH, Quivey JM, Venook AP, et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):809–816
  13. Reni M, Cereda S, Balzano G, et al. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2009 Nov64(6);1253–9.
  14. Kachnic LA, Shaw JE, Manning MA, et al. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Int J Cancer. 2001;96:132–139
  15. Spry N, Harvey J, Macleod C, et al. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. Int J Radiat Oncol Biol Phys. 2008;70(5):1438–1446
  16. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110(1):47–55
  17. Huguet F, Andre T, Hammel P, et al. Chemoradiotherapy (CRT) after chemotherapy (CT) improves survival for locally-advanced (LA) pancreatic cancer patients: retrospective analysis of 181 patients enrolled in prospective phases II and III GERCOR studies. J Clin Oncol. 2005;23(16S):4095
  18. Wilkowski R, Thoma M, Weingandt H, Dühmke E, Heinemann V. Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. JOP. 2005;6(2):216–230
  19. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–3516
  20. Cunningham D, Chau I, Stoken D, et al., NCRI Upper Gastrointestinal Cancer Clinical Study Group  Phase III randomized comparison of gemcitabine (GEM) vs gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Proc ECCO. 2005;13:
  21. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212–2217
  22. [No authors listed] . Gemcitabine plus bevacizumab no better than gemcitabine alone in clinical study of 600 patients with pancreatic cancer. Cancer Biol Ther. 2007;6(2):130
  23. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol. 2007;25(18S):LBA4509
  24. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–1966
  25. Milano MT, Chmura SJ, Garofalo MD, et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2004;59:445–453
  26. Ben-Joseph E, Shields AF, Vaishampayan U, et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;59:454–459
  27. Wilkowski R, Thoma M, Schauer T, Wagner A, Heinemann V. Effects of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg. 2004;28:1011–1018
  28. Gastrointestinal Tumour Study Group . Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751–755
  29. Shinchi H, Takao S, Noma H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2002;53(1):146–150
  30. Cardenes HR, Powell M, Loehrer PJ, et al. E4201: randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): quality-of-life (QOL) analysis. J Clin Oncol. 2009;27(15s):abstract 4627
  31. Henry A, Ryder W, Moore C, et al. Chemoradiotherapy for locally advanced pancreatic cancer: a radiotherapy dose escalation and organ motion study. Clin Oncol. 2008;20(7):541–547
  32. Murphy JD, Adusumilli S, Griffith KA, et al. Full dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):801–808

PII: S0936-6555(09)00324-0

doi: 10.1016/j.clon.2009.09.024

Clinical Oncology
Volume 22, Issue 1 , Pages 27-35 , February 2010

Article Tools

* Image Usage & Resolution